Kết quả ban đầu điều trị Ribociclib kết hợp nội tiết trên bệnh nhân ung thư vú tái phát, di căn có thụ thể nội tiết dương tính=Early outcome of Ribociclib combined with endocrine therapy in recurrent and metastatic hormone positive breast cancer

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Văn Quảng Lê, Thị Hòa Nguyễn, Thị Huyền Phùng

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Nghiên cứu y học (Đại học Y Hà Nội), 2024

Mô tả vật lý: tr.79-89

Bộ sưu tập: Metadata

ID: 244703

Thêm vào giỏ

Nghiên cứu nhằm đánh giá hiệu quả điều trị của ribociclib kết hợp thuốc nội tiết kháng men aromatase (AI) trên bệnh nhân ung thư vú (UTV) tái phát, di căn và một số tác dụng không mong muốn. Đây là nghiên cứu nghiên cứu mô tả trên 57 bệnh nhân UTV có thụ thể nội tiết dương tính, Her-2/neu âm tính từ 5/2021 - 8/2023. Tuổi trung bình là 51,5 ± 12,1. Có 61,4% bệnh nhân điều trị bước một và 38,6% ở bước sau. Thời gian điều trị trung bình là 12,1 ± 5,3 tháng, dài nhất là 23,5 tháng. Tỷ lệ đáp ứng hoàn toàn, một phần, bệnh giữ nguyên và bệnh tiến triển lần lượt là 1,8%
43,8%
50,8% và 3,6%. Trung vị thời gian sống thêm bệnh không tiến triển (PFS) là 16,9 tháng, liên quan có ý nghĩa thống kê với đáp ứng điều trị, p = 0,006. Tác dụng phụ thường gặp là hạ bạch cầu hạt (75,3%), tăng men gan (50,9%), hạ tiểu cầu (45,5%), mệt mỏi (33,3%). Phác đồ ribociclib kết hợp AI có hiệu quả, độc tính chấp nhận được, không có bệnh nhân tử vong vì độc tính của phác đồ.The study aims to evaluate the therapeutic efficacy of ribociclib combined with aromatase inhibitors (AI) in patients with recurrent and metastatic breast cancer (mBC) and its side effects. This is a retrospective study involving 57 mBC patients with hormone receptors positive and Her-2/neu negative from May 2021 to August 2023. The average age was 51.5 ± 12.1. 61.4% of patients were in the first line of treatment and 38.6% were in subsequent lines. The average treatment duration was 12.1 ± 5.3 months, with the longest being 23.5 months. The rates of complete response, partial response, stable disease, and progressive disease were 1.8%
43.8%
50.8%, and 3.6%, respectively. The median progression-free survival (PFS) was 16.9 months, significantly associated with treatment response (p = 0.006). Common side effects included neutropenia (75.3%), elevated liver enzymes (50.9%), thrombocytopenia (45.5%), and fatigue (33.3%). The ribociclib combined with AI regimen was effective, had acceptable toxicity, and there were no patient death due to the regimen's toxicity.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR